Repisaludmetadata only

Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.

González-Bertolín, Isabel et al.

Repisalud · Papers

antibodies antiviral-agents child immunization monoclonal preschool respiratory-syncytial-virus

antibody-dependent enhancement, immunization, nirsevimab, respiratory syncytial virus, antibodies, monoclonal, humanized, antiviral agents, child, child, preschool

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.

Related documents